JP2015506678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506678A5 JP2015506678A5 JP2014548965A JP2014548965A JP2015506678A5 JP 2015506678 A5 JP2015506678 A5 JP 2015506678A5 JP 2014548965 A JP2014548965 A JP 2014548965A JP 2014548965 A JP2014548965 A JP 2014548965A JP 2015506678 A5 JP2015506678 A5 JP 2015506678A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- loh
- megabase
- cancer cells
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 121
- 201000011510 cancer Diseases 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 96
- 210000003917 human chromosome Anatomy 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 57
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 25
- 239000012661 PARP inhibitor Substances 0.000 claims description 25
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 25
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 25
- 210000000349 chromosome Anatomy 0.000 claims description 24
- 239000012623 DNA damaging agent Substances 0.000 claims description 23
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 23
- 238000011269 treatment regimen Methods 0.000 claims description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 20
- 210000003765 sex chromosome Anatomy 0.000 claims description 20
- 238000004590 computer program Methods 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 16
- -1 radiation Substances 0.000 claims description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 10
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical group NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 10
- 229960001904 epirubicin Drugs 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 229950002133 iniparib Drugs 0.000 claims description 10
- 229960004768 irinotecan Drugs 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 10
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 10
- 229960000572 olaparib Drugs 0.000 claims description 10
- 229960000303 topotecan Drugs 0.000 claims description 10
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 8
- 108700010154 BRCA2 Genes Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000007547 defect Effects 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 7
- 101150072950 BRCA1 gene Proteins 0.000 claims description 6
- 101150008921 Brca2 gene Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 231100000518 lethal Toxicity 0.000 claims description 6
- 230000001665 lethal effect Effects 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 102000036365 BRCA1 Human genes 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 4
- 229950005566 picoplatin Drugs 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578713P | 2011-12-21 | 2011-12-21 | |
| US61/578,713 | 2011-12-21 | ||
| US201261654402P | 2012-06-01 | 2012-06-01 | |
| US61/654,402 | 2012-06-01 | ||
| PCT/US2012/071380 WO2013096843A1 (en) | 2011-12-21 | 2012-12-21 | Methods and materials for assessing loss of heterozygosity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076503A Division JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506678A JP2015506678A (ja) | 2015-03-05 |
| JP2015506678A5 true JP2015506678A5 (cg-RX-API-DMAC7.html) | 2016-02-04 |
| JP6325453B2 JP6325453B2 (ja) | 2018-05-16 |
Family
ID=48669561
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548965A Active JP6325453B2 (ja) | 2011-12-21 | 2012-12-21 | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2018076503A Active JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2020079997A Active JP7128853B2 (ja) | 2011-12-21 | 2020-04-30 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2022130844A Active JP7595619B2 (ja) | 2011-12-21 | 2022-08-19 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2024205398A Pending JP2025032160A (ja) | 2011-12-21 | 2024-11-26 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076503A Active JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2020079997A Active JP7128853B2 (ja) | 2011-12-21 | 2020-04-30 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2022130844A Active JP7595619B2 (ja) | 2011-12-21 | 2022-08-19 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2024205398A Pending JP2025032160A (ja) | 2011-12-21 | 2024-11-26 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9388472B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4497824A3 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6325453B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104160037B (cg-RX-API-DMAC7.html) |
| AU (4) | AU2012358244A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014015152A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2860312C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2794907T4 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2759533T5 (cg-RX-API-DMAC7.html) |
| FI (1) | FI2794907T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013096843A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| WO2012174378A2 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| WO2013096843A1 (en) | 2011-12-21 | 2013-06-27 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| US20180163271A1 (en) * | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| ES2800673T3 (es) * | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| WO2016185406A1 (en) | 2015-05-19 | 2016-11-24 | Nadathur Estates Pvt. Ltd. | Method for identification of a deficient brca1 function |
| WO2017191076A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| GB201607629D0 (en) * | 2016-05-01 | 2016-06-15 | Genome Res Ltd | Mutational signatures in cancer |
| CN109219852A (zh) * | 2016-05-01 | 2019-01-15 | 基因组研究有限公司 | 表征dna样品的方法 |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| CN107287285A (zh) * | 2017-03-28 | 2017-10-24 | 上海至本生物科技有限公司 | 一种预测同源重组缺失机制及患者对癌症治疗响应的方法 |
| EP3658687B1 (en) | 2017-07-25 | 2025-02-26 | Sophia Genetics S.A. | Methods for detecting biallelic loss of function in next-generation sequencing genomic data |
| CN112805563B (zh) * | 2018-05-18 | 2025-06-13 | 约翰·霍普金斯大学 | 用于评估和/或治疗癌症的无细胞dna |
| IT201900013335A1 (it) * | 2019-07-30 | 2021-01-30 | Menarini Silicon Biosystems Spa | Metodo per analizzare la perdita di eterozigosi (loh) a seguito di amplificazione totale del genoma basata su un sito di restrizione deterministico (drs-wga) |
| JP2023500460A (ja) * | 2019-10-29 | 2023-01-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 処置に対する分子応答に基づく処置の方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| CN112226495B (zh) * | 2020-12-18 | 2021-03-16 | 北京迈基诺基因科技股份有限公司 | 一种dna同源重组异常的检测方法及其应用 |
| WO2022150063A1 (en) * | 2021-01-10 | 2022-07-14 | Act Genomics (Ip) Co., Ltd. | Homologous recombination deficiency determining method and kit thereof |
| US20240026462A1 (en) * | 2021-01-10 | 2024-01-25 | Ying Ja CHEN | Homologous recombination deficiency determining method and kit thereof |
| CN113466417B (zh) * | 2021-05-13 | 2023-03-21 | 柳州东风容泰化工股份有限公司 | 一种氟尿嘧啶的制备纯度评估方法及系统 |
| US12188961B2 (en) | 2022-07-29 | 2025-01-07 | International Business Machines Corporation | Method for accurate pad contact testing |
| WO2024083971A1 (en) | 2022-10-19 | 2024-04-25 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
| WO2025173014A1 (en) | 2024-02-16 | 2025-08-21 | Onecell Diagnostics India Private Limited | A method for selecting ovarian cancer patients for parp inhibitor treatment |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| DE3630497A1 (de) | 1986-09-08 | 1988-03-10 | Behringwerke Ag | Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel |
| HU199492B (en) | 1987-05-08 | 1990-02-28 | Sankyo Co | Process for producing antitumour platinum complexes and pharmaceutical compositions comprising same |
| US4996337A (en) | 1987-06-23 | 1991-02-26 | American Cyanamid Company | Synthesis of cisplatin analogs |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5434256A (en) | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US4946954A (en) | 1989-01-17 | 1990-08-07 | Georgetown University | Platinum pharmaceutical agents |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| ZA928771B (en) | 1991-11-15 | 1993-09-08 | Smithkline Beecham Corp | Combination chemotherapy |
| CA2168096A1 (en) * | 1993-07-26 | 1995-02-02 | David E. Housman | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| US6384210B1 (en) | 1997-03-20 | 2002-05-07 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6214821B1 (en) | 1998-03-05 | 2001-04-10 | Washington State University Research Foundation | Methods and composition for the inhibition of cancer cells |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| GB9808145D0 (en) | 1998-04-17 | 1998-06-17 | Zeneca Ltd | Assay |
| US20030049613A1 (en) | 1998-08-17 | 2003-03-13 | Manuel Perucho | Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| JP2002534098A (ja) | 1999-01-06 | 2002-10-15 | コーネル リサーチ ファンデーション インク． | ゲノムシークエンシングにおける単一ヌクレオチドの多型の加速度的な同定およびクローンの整列化 |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| JP4287652B2 (ja) | 2000-10-24 | 2009-07-01 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | ゲノムｄｎａの直接多重処理による性状分析 |
| US7858331B2 (en) | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| EP1339402B1 (en) | 2000-12-01 | 2010-08-25 | Eisai Inc. | Azaphenanthridone derivatives and their use as parp inhibitors |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| CA2477611A1 (en) | 2002-03-01 | 2003-09-12 | Ravgen, Inc. | Rapid analysis of variations in a genome |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| WO2004072269A2 (en) | 2003-02-12 | 2004-08-26 | Mayo Foundation For Medical Education And Research | Bex4 nucleic acids, polypeptides, and method of using |
| US20040170983A1 (en) * | 2003-02-27 | 2004-09-02 | Danenberg Kathleen D. | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus |
| US20050112604A1 (en) | 2003-03-14 | 2005-05-26 | Akihide Fujimoto | Loss of heterozygosity of the DNA markers in the 12q22-23 region |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| EP1638509B1 (en) | 2003-07-02 | 2015-12-30 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| DK1660095T3 (da) | 2003-07-25 | 2010-05-25 | Cancer Rec Tech Ltd | Tricykliske PARP-inhibitorer |
| AU2004264421B2 (en) | 2003-08-13 | 2011-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
| US20080108057A1 (en) | 2004-06-22 | 2008-05-08 | Griffith Jeffrey K | Allelic imbalance in the diagnosis and prognosis of cancer |
| CA2584989A1 (en) | 2004-10-22 | 2006-05-04 | Sydney David Finkelstein | Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation |
| US20070070349A1 (en) | 2005-09-23 | 2007-03-29 | Helicos Biosciences Corporation | Optical train and method for TIRF single molecule detection and analysis |
| EP1856292B1 (en) | 2005-03-09 | 2013-10-30 | Abbott Laboratories | Diagnostic methods for identifying candidate patients for the treatment with trastuzumab. |
| US20060234264A1 (en) | 2005-03-14 | 2006-10-19 | Affymetrix, Inc. | Multiplex polynucleotide synthesis |
| EP1877576B1 (en) | 2005-04-12 | 2013-01-23 | 454 Life Sciences Corporation | Methods for determining sequence variants using ultra-deep sequencing |
| CA2605669A1 (en) | 2005-04-21 | 2006-11-02 | Ronald D. Alvarez | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
| WO2006128195A2 (en) | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
| EP1896491B1 (en) | 2005-06-30 | 2010-11-17 | Bionumerik Pharmaceuticals, Inc. | Monoazole ligand platinum analogs |
| EP1926835B1 (en) | 2005-09-21 | 2014-12-31 | BioArray Solutions Ltd. | Message abundance and allele copy number determination using ivt with single-stranded primer-promoter-selector constructs |
| US20080262062A1 (en) | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20090081237A1 (en) | 2007-03-12 | 2009-03-26 | Dana-Farber Cancer Institute | Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents |
| CA2698545C (en) | 2007-09-07 | 2014-07-08 | Fluidigm Corporation | Copy number variation determination, methods and systems |
| PL2209375T3 (pl) * | 2007-10-03 | 2014-12-31 | Eisai Inc | Związki, kompozycje i metody stosowania inhibitorów PARP |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP2224804A4 (en) | 2007-12-07 | 2011-06-01 | Bipar Sciences Inc | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS |
| US20090246789A1 (en) | 2008-03-25 | 2009-10-01 | University Of South Carolina | Gene Mutation Profiling of CSMD1 |
| US20100086922A1 (en) † | 2008-05-30 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
| JP5570516B2 (ja) | 2008-10-31 | 2014-08-13 | アッヴィ・インコーポレイテッド | 遺伝子コピー数の変化のパターンに基づいた結腸直腸癌のゲノム分類 |
| US8206910B2 (en) * | 2008-12-08 | 2012-06-26 | The Cleveland Clinic Foundation | Targets for use in diagnosis, prognosis and therapy of breast cancer |
| KR100925337B1 (ko) | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| WO2011048495A1 (en) | 2009-10-19 | 2011-04-28 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
| EP2539468A4 (en) | 2010-02-24 | 2013-08-28 | Myriad Genetics Inc | DIAGNOSTIC PROCEDURE INCLUDING LOSS OF HETEROZYGOTY |
| EP3327148B1 (en) * | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| WO2012019000A2 (en) | 2010-08-04 | 2012-02-09 | On-Q-ity | Biomarkers for the identification monitoring and treatment of ovarian cancer |
| DK2609216T3 (en) * | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| KR20210131432A (ko) | 2010-12-30 | 2021-11-02 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| WO2012174378A2 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| WO2013096843A1 (en) | 2011-12-21 | 2013-06-27 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| AU2014248007B2 (en) | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| US20180163271A1 (en) | 2014-01-16 | 2018-06-14 | Clovis Oncology, Inc. | Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity |
| ES2800673T3 (es) * | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| JP7259274B2 (ja) * | 2018-11-12 | 2023-04-18 | ソニーグループ株式会社 | 情報処理装置、情報処理方法、及びプログラム |
-
2012
- 2012-12-21 WO PCT/US2012/071380 patent/WO2013096843A1/en not_active Ceased
- 2012-12-21 JP JP2014548965A patent/JP6325453B2/ja active Active
- 2012-12-21 EP EP24191594.1A patent/EP4497824A3/en active Pending
- 2012-12-21 EP EP19199341.9A patent/EP3660161B1/en active Active
- 2012-12-21 ES ES12860530T patent/ES2759533T5/es active Active
- 2012-12-21 EP EP12860530.0A patent/EP2794907B2/en active Active
- 2012-12-21 CN CN201280070358.0A patent/CN104160037B/zh active Active
- 2012-12-21 CN CN201710172605.2A patent/CN107267598B/zh active Active
- 2012-12-21 CA CA2860312A patent/CA2860312C/en active Active
- 2012-12-21 AU AU2012358244A patent/AU2012358244A1/en not_active Abandoned
- 2012-12-21 DK DK12860530.0T patent/DK2794907T4/da active
- 2012-12-21 BR BR112014015152A patent/BR112014015152A2/pt not_active IP Right Cessation
- 2012-12-21 FI FIEP12860530.0T patent/FI2794907T4/fi active
-
2014
- 2014-06-18 US US14/307,708 patent/US9388472B2/en active Active
-
2016
- 2016-06-24 US US15/192,497 patent/US10612098B2/en active Active
-
2018
- 2018-04-12 JP JP2018076503A patent/JP6700333B2/ja active Active
- 2018-08-02 AU AU2018211277A patent/AU2018211277B2/en active Active
-
2020
- 2020-02-24 US US16/799,797 patent/US20200190602A1/en active Pending
- 2020-04-30 JP JP2020079997A patent/JP7128853B2/ja active Active
- 2020-08-28 AU AU2020223754A patent/AU2020223754B2/en active Active
-
2022
- 2022-08-19 JP JP2022130844A patent/JP7595619B2/ja active Active
- 2022-09-08 AU AU2022228167A patent/AU2022228167B2/en active Active
- 2022-12-14 US US18/081,586 patent/US20230111438A1/en active Pending
-
2024
- 2024-11-26 JP JP2024205398A patent/JP2025032160A/ja active Pending
-
2025
- 2025-03-21 US US19/087,361 patent/US20250215509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506678A5 (cg-RX-API-DMAC7.html) | ||
| JP7595619B2 (ja) | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| Marchini et al. | Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections | |
| ES2800673T3 (es) | Métodos y materiales para evaluar una deficiencia de recombinación homóloga | |
| Ueda et al. | Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis | |
| US9410206B2 (en) | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer | |
| Ghodousi et al. | MicroRNA‐326 and microRNA‐200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia | |
| den Brok et al. | Homologous recombination deficiency in breast cancer: a clinical review | |
| ES2777228T3 (es) | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer | |
| CN105308189B (zh) | 响应于抗癌疗法的肿瘤细胞标志物 | |
| Yuan et al. | Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients | |
| Momtazmanesh et al. | Long non-coding RNAs in diagnosis, treatment, prognosis, and progression of glioma: a state-of-the-art review | |
| Al-Khanbashi et al. | Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment | |
| Bozdag et al. | Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels | |
| US20140162887A1 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| Zhou et al. | Identification of driver copy number alterations in diverse cancer types and application in drug repositioning | |
| US10676791B2 (en) | Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma | |
| Peacock et al. | MicroRNAs: relevant tools for a colorectal surgeon? | |
| CN109628600A (zh) | 一种用于早期乳腺癌诊断的生物标志物 | |
| Pan et al. | MicroRNA expression profiling of Chinese follicular lymphoma by microarray: A preliminary study | |
| Jiang et al. | Microarray-based measurement of microRNA-449c-5p levels in hepatocellular carcinoma and bioinformatic analysis of potential signaling pathways | |
| Wang et al. | Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide | |
| CN116083579B (zh) | 用于非小细胞肺癌诊断的circRNA-miRNA-mRNA调控网络及其应用 | |
| WO2016077858A1 (en) | Biomarkers of disease and their use in disease detection and management |